Type 2 diabetes mellitus (T2DM) is a metabolic condition with an elevated impact on cardiovascular (CV) risk. The innovative therapeutic approaches for T2DM - incretin-based therapies (IBTs), including glucagon-like peptide 1 (GLP-1) receptor agonists, have become popular and more widely used in recent years. The available scientific data from clinical studies and clinical practice highlights their beyond glucose-lowering effects, which is achieved without any increase in hypoglycaemia. The former effects include reduction in body weight, lipids, blood pressure, inflammatory markers, oxidative stress, endothelial dysfunction, and subclinical atherosclerosis, thus reducing and potentially preventing CV events. In fact, the introduction of IBTs is one of the key moments in the history of diabetes research and treatment. Such therapeutic strategies allow customization of antidiabetic treatment to each patient's need and therefore obtain better metabolic control with reduced CV risk. The aim of the present paper is to provide a comprehensive overview of the effects of GLP-1RA on various cardiometabolic markers and overall CV risk, with particular attention on recent CV outcome studies and potential mechanisms. In particular, the effects of liraglutide on formation and progression of atherosclerotic plaque and mechanisms explaining its cardioprotective effects are highlighted.

Rizzo, M., Nikolic, D., Patti, A.M., Mannina, C., Montalto, G., McAdams, B.S., et al. (2018). GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR BASIS OF DISEASE, 1864(9), 2814-2821 [10.1016/j.bbadis.2018.05.012].

GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms

Rizzo, Manfredi;Nikolic, Dragana;Patti, Angelo Maria;Mannina, Carlo;Montalto, Giuseppe;
2018

Abstract

Type 2 diabetes mellitus (T2DM) is a metabolic condition with an elevated impact on cardiovascular (CV) risk. The innovative therapeutic approaches for T2DM - incretin-based therapies (IBTs), including glucagon-like peptide 1 (GLP-1) receptor agonists, have become popular and more widely used in recent years. The available scientific data from clinical studies and clinical practice highlights their beyond glucose-lowering effects, which is achieved without any increase in hypoglycaemia. The former effects include reduction in body weight, lipids, blood pressure, inflammatory markers, oxidative stress, endothelial dysfunction, and subclinical atherosclerosis, thus reducing and potentially preventing CV events. In fact, the introduction of IBTs is one of the key moments in the history of diabetes research and treatment. Such therapeutic strategies allow customization of antidiabetic treatment to each patient's need and therefore obtain better metabolic control with reduced CV risk. The aim of the present paper is to provide a comprehensive overview of the effects of GLP-1RA on various cardiometabolic markers and overall CV risk, with particular attention on recent CV outcome studies and potential mechanisms. In particular, the effects of liraglutide on formation and progression of atherosclerotic plaque and mechanisms explaining its cardioprotective effects are highlighted.
www.elsevier.com/locate/bbadis
Rizzo, M., Nikolic, D., Patti, A.M., Mannina, C., Montalto, G., McAdams, B.S., et al. (2018). GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR BASIS OF DISEASE, 1864(9), 2814-2821 [10.1016/j.bbadis.2018.05.012].
File in questo prodotto:
File Dimensione Formato  
BBA 2018.pdf

Solo gestori archvio

Dimensione 577.86 kB
Formato Adobe PDF
577.86 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/299148
Citazioni
  • ???jsp.display-item.citation.pmc??? 45
  • Scopus 77
  • ???jsp.display-item.citation.isi??? 74
social impact